Nancy J. Zeleznik-Le

Nancy J. Zeleznik-Le

Auto-generated profile, based on publicly available information

Nancy J. Zeleznik-Le

Department of Cancer Biology, Loyola University Chicago, Maywood, IL 60153

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2015 in Cell Reports
Verified
Journal Article
Open access
AKAravinda Kuntimaddi
Aravinda Kuntimaddi
NANicholas J. Achille
Nicholas J. Achille
JTJeremy Thorpe
Jeremy Thorpe
ALAlyson A. Lokken
Alyson A. Lokken
RSRitambhara Singh
Ritambhara Singh
JBJohn H. Bushweller
John H. Bushweller
The MLL gene is a common target of chromosomal translocations found in human leukemia. MLL-fusion leukemia has a consistently poor outcome. One of the most common translocation partners is AF9 (MLLT3). MLL-AF9 recruits DOT1L, a histone 3 lysine 79 methyltransferase (H3K79me1/me2/me3), leading to aberrant gene transcription. We show that DOT1L has three AF9 binding sites and present the nuclear magnetic resonance (NMR) solution structure of a DOT1L-AF9 complex. We generate structure-guided point mutations and find that they have graded effects on recruitment of DOT1L to MLL-AF9. Chromatin immunoprecipitation sequencing (ChIP-seq) analyses of H3K79me2 and H3K79me3 show that graded reduction of the DOT1L interaction with MLL-AF9 results in differential loss of H3K79me2 and me3 at MLL-AF9 target genes. Furthermore, the degree of DOT1L recruitment is linked to the level of MLL-AF9 hematopoietic transformation.

28 August 2014 in Hepatology
Verified
Journal Article
Open access
PDF file
NSNa Shang
Na Shang
MAMaribel Arteaga
Maribel Arteaga
AZAli Zaidi
Ali Zaidi
JSJimmy Stauffer
Jimmy Stauffer
SCScott J. Cotler
Scott J. Cotler
WQWei Qiu
Wei Qiu
Hepatocellular carcinoma (HCC) is the third most common cause of cancer death worldwide and most patients with HCC have limited treatment options. Focal adhesion kinase (FAK) is overexpressed in many HCC specimens, offering a potential target for HCC treatment. However, the role of FAK in hepatocarcinogenesis remains elusive. Establishing whether FAK expression plays a role in HCC development is necessary to determine whether it is a viable therapeutic target. In this study, we generated mice with hepatocyte‐specific deletion of Fak and investigated the role of Fak in an oncogenic (c‐MET/β‐catenin, MET/CAT)‐driven HCC model. We found that deletion of Fak in hepatocytes did not affect morphology, proliferation, or apoptosis. However, Fak deficiency significantly repressed MET/CAT‐induced tumor development and prolonged survival of animals with MET/CAT‐induced HCC. In mouse livers and HCC cell lines, Fak was activated by MET, which induced the activation of Akt/Erk and up‐regulated cyclin D1 and tumor cell proliferation. CAT enhanced MET‐stimulated FAK activation and synergistically induced the activation of the AKT/ERK‐cyclin D1 signaling pathway in a FAK kinase‐dependent manner. In addition, FAK was required for CAT‐induced cyclin D1 expression in a kinase‐independent fashion. Conclusion: Fak is required for c‐Met/β‐catenin‐driven hepatocarcinogenesis. Inhibition of FAK provides a potential strategy to treat HCC. (Hepatology 2015;61:214–226)

7 July 2020 in Blood Cancer Discovery
Verified
Journal Article
Closed access
PDF file
CSCharles R. Schmidt
Charles R. Schmidt
NANicholas J. Achille
Nicholas J. Achille
AKAravinda Kuntimaddi
Aravinda Kuntimaddi
ABAdam M. Boulton
Adam M. Boulton
BLBenjamin I. Leach
Benjamin I. Leach
JBJohn H. Bushweller
John H. Bushweller
MLL is a target of chromosomal translocations in acute leukemias with poor prognosis. The common MLL fusion partner AF9 (MLLT3) can directly bind to AF4, DOT1L, BCOR, and CBX8. To delineate the relevance of BCOR and CBX8 binding to MLL-AF9 for leukemogenesis, here we determine protein structures of AF9 complexes with CBX8 and BCOR, and show that binding of all four partners to AF9 is mutually exclusive. Using the structural analyses, we identify point mutations that selectively disrupt AF9 interactions with BCOR and CBX8. In bone marrow stem/progenitor cells expressing point mutant CBX8 or point mutant MLL-AF9, we show that disruption of direct CBX8/MLL-AF9 binding does not impact in vitro cell proliferation, whereas loss of direct BCOR/MLL-AF9 binding causes partial differentiation and increased proliferation. Strikingly, loss of MLL-AF9/BCOR binding abrogated its leukemogenic potential in a mouse model. The MLL-AF9 mutant deficient for BCOR binding reduces the expression of the EYA1 phosphatase and the protein level of c-Myc. Reduction in BCOR binding to MLL-AF9 alters a MYC-driven gene expression program, as well as altering expression of SIX-regulated genes, likely contributing to the observed reduction in the leukemia-initiating cell population. Significance: Direct recruitment of BCOR to MLL-AF9 is essential for leukemia via EYA1 phosphatase regulation, altering MYC and SIX gene expression programs. Specific partner binding (AF4, DOT1L, and BCOR) contributes in distinct ways to MLL leukemia. This may provide a rationale for combination DOT1L and EYA1 inhibition for MLL fusion leukemia treatment. This article is highlighted in the In This Issue feature, p. 127

18 February 2019 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
CPCynthia Perez
Cynthia Perez
KPKushal Prajapati
Kushal Prajapati
BBBrianna Burke
Brianna Burke
LPLourdes Plaza-Rojas
Lourdes Plaza-Rojas
NZNancy J. Zeleznik-Le
Nancy J. Zeleznik-Le
JGJose A Guevara-Patino
Jose A Guevara-Patino
Background The development of memory responses is an evolutionary function of the adaptive immune system. We propose that for the immune system to populate the memory compartment with the best-suited CD8 T cells it utilizes a process of certification or molecular accreditation mediated through Natural Killer Group 2D (NKG2D). This process of certification assures that the memory compartment is filled with CD8 T cells that have demonstrated their ability to kill their cognate targets through a two-step process that utilizes T cell receptor (TCR) and NKG2D signaling. Methods One week after immunization with peptide-pulsed dendritic cells, NKG2D signaling was transiently blocked in vivo with a single injection of neutralizing antibodies. Under such conditions, we determined the importance of NKG2D signaling during the effector phase for memory formation without compromising NKG2D signaling at the memory phase. Both open (polyclonal) and closed (monoclonal) CD8 T cell repertoires were studied. Results We show that signaling through NKG2D mediated this certification. Temporary blockade of NKG2D signaling during the effector phase resulted in the formation of highly defective memory CD8 T cells characterized by altered expression of the ribosomal protein S6 and epigenetic modifiers, suggesting modifications in the T cell translational machinery and epigenetic programming. Finally, these uncertified memory cells were not protective against a B16 tumor challenge. Conclusion Signaling through NKG2D during the effector phase (certification) favors the development of functional memory CD8 T cells, a previously undescribed role for NKG2D. Temporary blockade of NKG2D signaling during the effector phase results in the formation of highly defective memory CD8 T cells potentially by affecting the expression of the ribosomal protein S6 and epigenetic modifiers, suggesting alterations in T cell translational machinery and epigenetic programming.

1 May 2015 in Cancer Genetics
Verified
Journal Article
Closed access
SBSonia Brockway
Sonia Brockway
NZNancy J. Zeleznik-Le
Nancy J. Zeleznik-Le

1 March 2016 in Leukemia Research
Verified
Journal Article
Closed access
NANicholas J. Achille
Nicholas J. Achille
MOMegan Othus
Megan Othus
KPKathleen Phelan
Kathleen Phelan
SZShubin Zhang
Shubin Zhang
KCKathrine Cooper
Kathrine Cooper
NZNancy J. Zeleznik-Le
Nancy J. Zeleznik-Le